Abstract: The present invention relates to a composition for preventing or treating heart failure including TREM2 protein or a fragment thereof as an active ingredient. The TREM2 protein or fragment thereof according to the present invention can be prepared as a soluble form and used as an injection, and when injected into the body, it promotes functional and structural improvement of the infarcted heart, and is effective for preventing or treating heart failure, and more specifically, it can be advantageously used for preventing or treating heart failure that appears as a sequela of myocardial infarction.

Abstract: The present invention relates to: a biomarker composition for diagnosing or predicting the prognosis of thyroid cancer, comprising a preparation capable of detecting a mutation in a PLEKHS1 promoter gene; and a use thereof. The biomarker composition for diagnosing or predicting the prognosis of thyroid cancer of the present invention confirms whether a mutation is present in a PLEKHS1 promoter gene, and thus can provide information needed for diagnosing metastatic (distant metastatic) differentiated thyroid cancer, and also confirms whether a mutation is present in BRAF, TERT promoter, three types of RAS and a TP53 gene in addition to the PLEKHS1 promoter gene, and thus, with respect to radioactive iodine therapy response and survival, can classify the prognosis of a metastatic differentiated thyroid cancer patient into one of three prognosis groups, and predict the same.

Abstract: The present invention relates to a method of predicting the risk of developing ankylosing spondylitis using DNA copy number variation. It was verified that the risk of developing ankylosing spondylitis can be effectively predicted using primers for detecting DNA copy number variation, of the present invention, and the sensitivity and specificity of prediction can be improved by grafting the results of single nucleotide polymorphism (SNP) measurements, and thus more fundamental approaches for preventing and treating ankylosing spondylitis are expected.

Abstract: The present invention relates to a probe for detecting drug-resistant gram-positive pathogens, a probe set, and a method of detecting drug-resistant gram-positive pathogens using them. The probe for detecting drug-resistant gram-positive pathogens, the probe set, and the method for detecting drug-resistant gram-positive pathogens using them according to the present invention can contribute not only to shortening a detection time, compared to a conventional detection time, by optimizing a hybridization time, but also to increasing the sensitivity of detection by pre-amplification of the specific sequence of drug-resistant gram-positive pathogens, and thereby multiple detections of drug-resistant gram-positive pathogens can be accurately and efficiently performed.

Abstract: The present invention relates to a method of predicting the risk of developing ankylosing spondylitis using DNA copy number variation. It was verified that the risk of developing ankylosing spondylitis can be effectively predicted using primers for detecting DNA copy number variation, of the present invention, and the sensitivity and specificity of prediction can be improved by grafting the results of single nucleotide polymorphism (SNP) measurements, and thus more fundamental approaches for preventing and treating ankylosing spondylitis are expected.

Abstract: The present application discloses a diagnostic method and a kit for prognosis assessment of colorectal cancer (CRC) and a novel tumor suppressor gene to be used for diagnosis of colorectal cancer (CRC), the method comprising the steps of: (a) identifying recurrently altered regions (RAR) on a chromosome; and (b) detecting genomic alterations in the RAR. The present method makes it possible to perform early diagnosis as well as prognosis assessment for various cancers and tumors including colorectal cancer (CRC).

Abstract: The invention provides diagnostic methods for determining the prognosis of hepatocellular carcinoma (HCC) comprising the steps of (a) observing recurrently altered genomic region on a chromosome; (b) measuring variation of one or more of RAR expression variations selected from the RAR variation group consists of gains of RAR-G1 to RAR-G14 and losses of RAR-L1 to RAR-L18 as defined in table 1, a diagnostic kit, and genes for useful in diagnosis or prognosis of liver cancer.

Abstract: The present application discloses a diagnostic method and a kit for prognosis assessment of colorectal cancer (CRC) and a novel tumor suppressor gene to be used for diagnosis of colorectal cancer (CRC), the method comprising the steps of: (a) identifying recurrently altered regions (RAR) on a chromosome; and (b) detecting genomic alterations in the RAR. The present method makes it possible to perform early diagnosis as well as prognosis assessment for various cancers and tumors including colorectal cancer (CRC).